Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Next Previous
Search
Trial Profile

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANK-700 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man
  • Acronyms MoveS-it
  • Sponsors Anokion

    • Most Recent Events

    • 18 Sep 2024 According to an Anokion media release, company announced that the data of this trial will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) being held September 18-20, 2024 in Copenhagen, Denmark.
    • 29 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2023 According to an Anokion media release, company has completed patient enrollment early in the second and final MAD cohort for this study. The study will continue with a 12-month safety follow-up expected to complete in the first half of 2024. Company anticipates reporting full results from its MoveS-it clinical trial in the second half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top